The Active Pharmaceutical Ingredients industry holds a promise of remarkable growth in the forthcoming years. Continuing our growth journey, we have made significant investments towards the research and development of new products of distinct therapeutic categories and have launched them in the market over the last few years. Starting from pilot phase development to scaling up in large batches to commercial production, IOL has been notably successful in launching six products in the market in a short span. All the newly launched and commercialized products are generic APIs and possess robust growth potential in the pharmaceutical market.
Metformin is an antihyperglycemic agent and is the most prioritised drug for managing type 2 diabetes. Belonging to the biguanide class, It reduces hepatic glucose production and betters the insulin sensitivity of body tissues by improving glucose utilisation. With changing lifestyles and almost half a billion people, currently living with diabetes worldwide, Metformin has appeared to be an efficient solution and is tipped to reach a hefty market size in 2025 at a CAGR of 5.5%.
Clopidogrel is an Antiplatelet agent, used for reducing the risk of myocardial infarction and stroke. The active molecules bind to the ADP receptors, thereby restricting the platelet accumulation in the body. Finding a place in WHO’s list of essential medicines, the drug is in significant demand, and has proven to be superior to many drugs in reducing adverse cardiovascular outcomes.
Belonging to the class of Proton Pump Inhibitors (PPI’s), Pantoprazole is used to reduce excess acid created by the stomach and avoids further damage to the esophagus caused by GERD. It acts by binding to the enzyme system at the secretory surface of gastric wall. With an accelerated pace of life leading to chronic health issues, India counters more than 10 million cases of digestive disorder each year which highlights the growing demand for the drug, especially when it is being shown to prevent cancer of esophagus.
An antihyperlipidemic agent, Fenofibrate is used to reduce “bad” cholesterol and Triglycerides, and increase the “good” cholesterol in the blood. It activates the nuclear receptor proteins which eliminates the triglyceride rich particles from blood plasma. As per WHO, cardiac disorders account for 31% of all deaths each year. Further, with changing demographics, easy availability and healthy adoption in both developed and developing countries, Fenofibrate is projected to achieve exponential growth and have the largest market share in Fibrate drug segment by 2026.
Lamotrigine is an anticonvulsant drug used for treating epilepsy and as a mood stabilizer in bipolar disorder. It restricts the voltage sensitive sodium channels which stabilizes the neuronal membranes. Health research firms have forecasted the active epilepsy cases to reach 59 million worldwide by 2027. Clinical efficacy of the drug in certain neuropathic pain states is also being considered.
Categorised into the class of anticholelithic drugs, Ursodeoxycholic acid is used for dissolution of cholestrol rich gallstones and for treating the bile flow from liver. It suppresses liver synthesis, secretion of cholestrol and further restricts its absorption in the intestine resulting in the removal of gallstones. With increasing prevalence of liver cirrhosis particularly in the Indian subcontinent and about 15% of the US population being affected by gallstones annually, the UDCA market is expected to witness a CAGR of 11.9% over the next 5 years.
Affiliated to the Anticonvulsant drug class, Gabapentin is used to treat partial seizures, neuropathic pain, hot flashes and restless legs syndrome. The drug interacts with high voltage calcium channels in brain membranes and increases GABA synthesis. It has emerged as a preferred choice of treatment in postherpetic neuralgia and central neuropathic pain. Excessive alcohol intake, chemotherapy, diabetes and thyroid problems have appeared as common causes for neuropathic pain and are deemed to be the driving forces for the drug demand.